|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for MAP3K5 |
 Gene summary |
| Basic gene Info. | Gene symbol | MAP3K5 |
| Gene name | mitogen-activated protein kinase kinase kinase 5 | |
| Synonyms | ASK1|MAPKKK5|MEKK5 | |
| Cytomap | UCSC genome browser: 6q22.33 | |
| Type of gene | protein-coding | |
| RefGenes | NM_005923.3, | |
| Description | ASK-1MAP/ERK kinase kinase 5MAPK/ERK kinase kinase 5MEK kinase 5MEKK 5apoptosis signal regulating kinase 1apoptosis signal-regulating kinase 1 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 602448 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000197442 | ||
| HPRD : 03904 | ||
| Vega : OTTHUMG00000015647 | ||
| Protein | UniProt: Q99683 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_MAP3K5 | |
| BioGPS: 4217 | ||
| Pathway | NCI Pathway Interaction Database: MAP3K5 | |
| KEGG: MAP3K5 | ||
| REACTOME: MAP3K5 | ||
| Pathway Commons: MAP3K5 | ||
| Context | iHOP: MAP3K5 | |
| ligand binding site mutation search in PubMed: MAP3K5 | ||
| UCL Cancer Institute: MAP3K5 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0000165 | MAPK cascade | 17210579 | GO:0000186 | activation of MAPKK activity | 11959862 | GO:0006468 | protein phosphorylation | 15983381 | GO:0006919 | activation of cysteine-type endopeptidase activity involved in apoptotic process | 14761963 | GO:0007254 | JNK cascade | 21771788 | GO:0008631 | intrinsic apoptotic signaling pathway in response to oxidative stress | 21771788 | GO:0043065 | positive regulation of apoptotic process | 21771788 | GO:0043280 | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 20674765 | GO:0070301 | cellular response to hydrogen peroxide | 20674765 |
| Top |
| Ligand binding site mutations for MAP3K5 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | S821 | K819N | KIRC | 1 | D807 | K805R | KIRC | 1 | K709 | E710K | SKCM | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for MAP3K5 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | S821 | K819N | -0.85032717 | K709 | E710K | -0.63932577 | D807 | K805R | -0.5558398 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for MAP3K5 from PDB |
| Top |
| Differential gene expression and gene-gene network for MAP3K5 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for MAP3K5 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0011849 | Diabetes Mellitus | 4 | Biomarker |
| umls:C0030567 | Parkinson Disease | 2 | AlteredExpression, Biomarker |
| umls:C0025202 | Melanoma | 2 | Biomarker, GeneticVariation |
| umls:C0878544 | Cardiomyopathies | 1 | Biomarker |
| umls:C0011853 | Diabetes Mellitus, Experimental | 1 | Biomarker |
| umls:C0860207 | Drug-Induced Liver Injury | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for MAP3K5 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of MAP3K5 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | IEO | 3-CYANO-4-(PIPERIDIN-4-YLOXY)-1H-INDOLE-7- CARBOXAMIDE | 4bib | B | D807 | STU | STAUROSPORINE | 2clq | A | D807 S821 | STU | STAUROSPORINE | 2clq | B | D807 S821 | STU | STAUROSPORINE | 4bf2 | A | D807 S821 | IEO | 3-CYANO-4-(PIPERIDIN-4-YLOXY)-1H-INDOLE-7- CARBOXAMIDE | 4bib | A | D807 S821 | IM6 | 4-TERT-BUTYL-N-[6-(1H-IMIDAZOL-1-YL)IMIDAZO[1,2- A]PYRIDIN-2-YL]BENZAMIDE | 3vw6 | B | K709 | BH9 | 4-TERT-BUTYL-N-[6-(1H-PYRAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDIN-2-YL]BENZAMIDE | 4bhn | A | K709 | BH9 | 4-TERT-BUTYL-N-[6-(1H-PYRAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDIN-2-YL]BENZAMIDE | 4bhn | B | K709 | IE6 | N-(2-AMINOETHYL)-5-{2-METHYL-1H-PYRROLO[2,3- B]PYRIDIN-4-YL}THIOPHENE-2-SULFONAMIDE | 4bie | A | K709 | IE4 | N-(2-AMINOETHYL)-5-{1H-PYRROLO[2,3-B]PYRIDIN- 3-YL}THIOPHENE-2-SULFONAMIDE | 4bic | A | K709 D807 | IE8 | 5-[(1R)-2-AMINO-1-PHENYLETHOXY]-2-(FURAN-3- YL)-3-{1H-PYRROLO[2,3-B]PYRIDIN-3-YL} PYRIDINE | 4bid | A | K709 D807 | IE8 | 5-[(1R)-2-AMINO-1-PHENYLETHOXY]-2-(FURAN-3- YL)-3-{1H-PYRROLO[2,3-B]PYRIDIN-3-YL} PYRIDINE | 4bid | B | K709 D807 | IE6 | N-(2-AMINOETHYL)-5-{2-METHYL-1H-PYRROLO[2,3- B]PYRIDIN-4-YL}THIOPHENE-2-SULFONAMIDE | 4bie | B | K709 D807 | STU | STAUROSPORINE | 4bf2 | B | K709 D807 S821 | IM6 | 4-TERT-BUTYL-N-[6-(1H-IMIDAZOL-1-YL)IMIDAZO[1,2- A]PYRIDIN-2-YL]BENZAMIDE | 3vw6 | A | K709 S821 |
| Top |
| Conservation information for LBS of MAP3K5 |
| Multiple alignments for Q99683 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |